SOFW SOFWAVE MEDICAL LTD

Sofwave™ Granted FDA Clearance For Latest Innovation: The “Precise” SUPERB™ Applicator

Sofwave™ Granted FDA Clearance For Latest Innovation: The “Precise” SUPERB™ Applicator

  • “Precise” delivers the same SUPERB™ technology in a compact applicator head for more convenient and precise treatment of smaller curved areas, such as around the eyes and mouth
  • The modular, smaller applicator head and its benefits are a direct add-on feature requiring no modification to current SUPERB™ console systems

SAN CLEMENTE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, announced today receipt of U.S. Food and Drug Administration (FDA) clearance of the Company’s 510(k) notification submission for its “Precise” compact SUPERB™ applicator to improve facial lines and wrinkles, lift the eyebrow, and lift lax submental (beneath the chin) and neck tissue; which can also affect the appearance of lax tissue in the submental and neck regions. The “Precise” applicator is also FDA cleared for short-term improvement in the appearance of cellulite.

“Following the recent FDA clearance of Sofwave’s SUPERB™ technology for the short-term improvement of cellulite last December, we are delighted to introduce the new “Precise” applicator to existing and prospective customers,” said Louis Scafuri, CEO of Sofwave Medical. “The compact applicator transducer array delivers the same safe and effective Synchronous Ultrasound Parallel Beam technology of existing large size applicators, but has been further refined with a condensed transducer configuration for more precise and convenient delivery of pulses around small, curved areas, such as the eyes and mouth. We expect this enhanced feature set and applicator configuration will be well received by Sofwave customers, and intend to leverage the new Precise applicator in additional indications in the future.”

Sofwave’s SUPERB™ System consists of two main functional components: 1) the console and 2) the applicator. The console includes the power sources, cooling unit, electrical components and the user interface. The applicator is comprised of an array of ultrasonic transducers that emit continuous acoustic waves and an active cooling element that is used to cool the skin area in contact with the applicator’s transducers.

“We continue to add functional yet transformational feature sets to the initial SUPERB™ platform’s design,” said Dr. Shimon Eckhouse, Chairman & Co-Founder. “The Precise SUPERB ™ will enable treatment of hard to reach anatomical sites with the ability to accurately target the area of treatment and with a superior ergonomic design while delivering the same safe, comfortable and highly effective treatment.”

About Sofwave Medical

 has implemented an innovative approach to wrinkle reduction lifting and cellulite using proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology is FDA-cleared head to improve facial lines and wrinkles, lift the eyebrow, and lift lax submental (beneath the chin) and neck tissue; which can also affect the appearance of lax tissue in the submental and neck regions and for short-term improvement in the appearance of cellulite providing physicians with smart yet simple, effective, and safe aesthetic solutions for their patients. Contact: 

Investor Contact:

Brian Ritchie

LifeSci Advisors LLC

(212) 915-2578



EN
15/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SOFWAVE MEDICAL LTD

 PRESS RELEASE

Sofwave Medical Reports Preliminary, Unaudited, Fourth Quarter and Ful...

Sofwave Medical Reports Preliminary, Unaudited, Fourth Quarter and Full Fiscal Year 2025 Topline Financial Results SAN CLEMENTE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced preliminary financial results for the fourth quarter and full fiscal year, for the period ended December 31, 2025. Preliminary Financial Results Fourth quarter 2025 revenue is expected to total between $28.6 million and $28.9 million, as compared to approximately $1...

 PRESS RELEASE

Sofwave Medical Reports Third Quarter 2025 Financial Results and Busin...

Sofwave Medical Reports Third Quarter 2025 Financial Results and Business Highlights —  Record quarterly revenue in third quarter of $21.1M, +56% year-over-year growth; IFRS gross margin of 73.7%  — Third quarter pulse recurring revenue of $8.3M, +55% year-over-year growth — First nine months revenue of $58.7M, +42% year-over-year growth; IFRS gross margin of 75.1% — First nine months IFRS and non-IFRS net income of $1.4M and $3.2M, respectively, versus a net loss of $3.8M and $2.1M, respectively, in the same year ago period — Approximately 667,00 pulse treatments administered...

 PRESS RELEASE

Sofwave to Participate in Upcoming November Investor Conferences

Sofwave to Participate in Upcoming November Investor Conferences SAN CLEMENTE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that management will participate in the following investor conferences: Stifel 2025 Healthcare ConferencePresentation Format: Corporate overviewPresentation Date: Wednesday, November 12, 2025Presentation Time: 10:40 a.m. ETWebcast: Jefferies London Healthcare Conference Presentation Format: Corporate overviewPresentation Date: ...

 PRESS RELEASE

Sofwave to Participate in the Jefferies Virtual Private MedTech Summit

Sofwave to Participate in the Jefferies Virtual Private MedTech Summit SAN CLEMENTE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the Jefferies Virtual Private MedTech Summit on October 1st, 2025. About Sofwave Medical has implemented an innovative approach to wrinkle reduction lifting and cellulite using its proprietary breakthrough technology...

 PRESS RELEASE

Sofwave Receives FDA, Pre-market Clearance for Pure Impact VIPTM Stand...

Sofwave Receives FDA, Pre-market Clearance for Pure Impact VIPTM Standalone EMS Device For Comprehensive Multi-Body Area Muscle Strengthening and Firming The Pure Impact VIP™ standalone device represents a major extension of the Pure Impact™ product line and introduces an all-in-one independent unitStandalone device is launched with an enhanced Pure Impact™ feature set which provides comprehensive muscle strengthening programs that focus on multiple body areas including the: abdomen, arms, thighs, and buttocks and enables simultaneous treatment of 6 muscle groupsIn the recent McKinsey Life ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch